TF
MRNA icon

Tompkins Financial’s Moderna MRNA Stock Holding History

Tompkins Financial’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10
Closed -$508 – 579
2026
Q1 		$508 Hold
10
– – ﹤0.01% 549
2025
Q4 		$295 Hold
10
– – ﹤0.01% 627
2025
Q3 		$258 Hold
10
– – ﹤0.01% 537
2025
Q2 		$276 Hold
10
– – ﹤0.01% 536
2025
Q1 		$284 Sell
10
-500
-98% -$17.7K ﹤0.01% 555
2024
Q4 		$21.2K Buy
510
+283
+125% +$13.5K ﹤0.01% 385
2024
Q3 		$15.2K Buy
227
+217
+2,170% +$19.9K ﹤0.01% 441
2024
Q2 		$1.19K Hold
10
– – ﹤0.01% 556
2024
Q1 		$1.07K Hold
10
– – ﹤0.01% 597
2023
Q4 		$995 Sell
10
-250
-96% -$21K ﹤0.01% 611
2023
Q3 		$26.9K Sell
260
-218
-46% -$24.3K ﹤0.01% 381
2023
Q2 		$58.1K Buy
478
+350
+273% +$46.7K 0.01% 319
2023
Q1 		$19.7K Buy
128
+118
+1,180% +$19.5K ﹤0.01% 421
2022
Q4 		$2K Hold
10
– – ﹤0.01% 573
2022
Q3 		$1K Hold
10
– – ﹤0.01% 580
2022
Q2 		$1K Hold
10
– – ﹤0.01% 563
2022
Q1 		$2K Buy
+10
New +$1.68K ﹤0.01% 568

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Tompkins Financial's MRNA Position: Q2 2026 in Review

Tompkins Financial sold out of Moderna (MRNA) in Q2 2026, closing a stake of 10 shares — an estimated $508 sold.

Tompkins Financial first reported a position in MRNA in Q1 2022 and held it in 17 quarters. The position peaked at $58.1K in Q2 2023. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Tompkins Financial reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Tompkins Financial sold 10 Moderna shares in Q2 2026, an estimated $508.
  • Tompkins Financial first reported a position in Moderna in Q1 2022 and held it in 17 quarters.
  • Tompkins Financial's Moderna position peaked at $58.1K in Q2 2023.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Tompkins Financial's 13F filing for Q2 2026, filed 15 Jul 2026.